Idorsia (OTCMKTS:IDRSF – Get Free Report) is expected to issue its resultson Thursday, July 30th. Analysts expect Idorsia to post earnings of ($0.2412) per share and revenue of $61.2360 million for the quarter.
Idorsia Price Performance
Shares of IDRSF stock opened at $7.60 on Thursday. Idorsia has a 52 week low of $3.30 and a 52 week high of $8.00. The firm has a 50 day moving average of $6.67 and a two-hundred day moving average of $5.29.
Wall Street Analyst Weigh In
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Idorsia in a research report on Monday, June 22nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Idorsia currently has a consensus rating of “Moderate Buy”.
About Idorsia
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
Recommended Stories
- Five stocks we like better than Idorsia
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
